Karyopharm Therapeutics Inc.(KPTI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,858 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
KPTI Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Karyopharm Therapeutics Inc. (KPTI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KPTI at 15.1/100 on a 32-signal composite quality model, placing it at rank #2,858 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (0.3) and institutional flow (5.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Karyopharm Therapeutics Inc. reports quarterly revenue of $33.4M, net income of $-67.0M. Top institutional holders of KPTI by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., ADAGE CAPITAL PARTNERS GP, L.L.C., ACORN CAPITAL ADVISORS, based on the most recent SEC filings. KPTI trades on the Nasdaq exchange and files with the SEC under CIK 1503802. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KPTI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Karyopharm Therapeutics Inc. directly from SEC EDGAR. Karyopharm Therapeutics Inc.'s 13F Pro composite quality score has ranged between 15 and 31 since 2021, currently 15.1 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$33.4M
Net Income
Q2 2026
$-67.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+0.6% YoYNet Income
-156.5% YoYOperating Income
+24.1% YoYEPS (Diluted)
-28.1% YoYTotal Assets
-34.1% YoYTotal Debt
Op. Cash Flow
+40.9% YoYFree Cash Flow
+40.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $146.1M +0.6% | $145.2M -0.5% | $146.0M -7.0% | $157.1M -25.1% | $209.8M +94.1% | $108.1M |
| Net Income | $-196.0M -156.5% | $-76.4M +46.6% | $-143.1M +13.4% | $-165.3M -33.2% | $-124.1M +36.8% | $-196.3M |
| Operating Income | $-90.7M +24.1% | $-119.4M +7.8% | $-129.5M +8.9% | $-142.2M -44.7% | $-98.3M +42.8% | $-171.8M |
| EPS (Diluted) | $-17.93 -28.1% | $-14.00 +25.5% | $-18.79 -830.2% | $-2.02 -22.4% | $-1.65 +39.3% | $-2.72 |
| Total Assets | $108.4M -34.1% | $164.4M -31.6% | $240.4M -32.9% | $358.2M +17.3% | $305.3M -2.5% | $313.1M |
| Total Debt | — | — | — | — | $169.3M | — |
| Operating Cash Flow | $-75.4M +40.9% | $-127.5M -37.5% | $-92.7M +38.0% | $-149.6M -39.6% | $-107.1M +33.2% | $-160.2M |
| Free Cash Flow | $-75.4M +40.9% | $-127.6M -37.6% | $-92.7M +38.0% | $-149.7M -39.5% | $-107.3M +33.1% | $-160.4M |
Get alerted when KPTI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Karyopharm Therapeutics Inc. including:
Top Institutional Holders of KPTI
RA CAPITAL MANAGEMENT, L.P.
$18.7M1,917,354 shADAGE CAPITAL PARTNERS GP, L.L.C.
$14.9M1,521,322 shACORN CAPITAL ADVISORS, LLC
$14.8M1,518,113 shGOLDMAN SACHS GROUP INC
$13.9M1,424,658 shBlackRock, Inc.
$13.9M1,418,799 shVANGUARD CAPITAL MANAGEMENT LLC
$9.4M958,979 shCatalio Capital Management, LP
$9.2M940,855 shAvidity Partners Management LP
$9.0M924,487 shT. Rowe Price Investment Management, Inc.
$7.7M786,309 shTWO SIGMA INVESTMENTS, LP
$6.8M695,264 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $18.7M | 1,917,354 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $14.9M | 1,521,322 |
| ACORN CAPITAL ADVISORS, LLC | $14.8M | 1,518,113 |
| GOLDMAN SACHS GROUP INC | $13.9M | 1,424,658 |
| BlackRock, Inc. | $13.9M | 1,418,799 |
| VANGUARD CAPITAL MANAGEMENT LLC | $9.4M | 958,979 |
| Catalio Capital Management, LP | $9.2M | 940,855 |
| Avidity Partners Management LP | $9.0M | 924,487 |
| T. Rowe Price Investment Management, Inc. | $7.7M | 786,309 |
| TWO SIGMA INVESTMENTS, LP | $6.8M | 695,264 |
Companies Similar to KPTI
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Gossamer Bio, Inc.
Outset Medical, Inc.
uniQure N.V.
Equillium, Inc.
Avalo Therapeutics, Inc.
UroGen Pharma Ltd.
Pulmonx Corp
Xencor Inc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put KPTI on your watchlist
Track score changes the day Karyopharm Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KPTI a good stock to buy?
13F Pro's AI-powered analysis of Karyopharm Therapeutics Inc. (KPTI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KPTI are available on the KPTI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KPTI is classified as a small company.
Which hedge funds own KPTI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KPTI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Karyopharm Therapeutics Inc.'s investment landscape.